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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is a rare malignancy with an incidence of 0.5-2 per 100,000 in 
Europe and the United States [1]. NPC has high prevalence in certain regions of the world, especially in 
Southeast Asia with a poor prognosis. In Indonesia, the prevalence  of NPC is 6.2/100 000, with 13 000 yearly 
new cases, [2]. NPC is the forth most cancer found in Indonesia.. 
Case Report: This paper reported a case of 39 years old man with nasopharyngeal carcinoma and subsequently 
underwent concurrent chemoradiotherapy (CCRT). 
Conclusion: The purpose of this paper is to explain experience at one of the largest single-centre of weekly 
cisplatin concurrently with radiotherapy with potential to be an optimal therapeutic regiment in the nonsurgical 
management of squamous cell carcinoma of head and neck (SCCHN) clinical stage III. 
Keywords:  
Nasopharyngeal carcinoma, stage III, concurrent, 
chemo radiotherapy 
*Corresponding author:  
Address: ORL-HNS Department, Oncology 
Division, Gatot Soebroto Central Army Hospital 
 
e-mail: fdaniltop@gmail.com 
 
1. CASE REPORT 
Nasopharyngeal carcinoma (NPC) has low incidence in Europe and the 
United States but relatively common in Southeast Asia, Southern China, the 
Arctic, and North Africa, especially in Southern China [3, 4]. The primary 
and only curative treatment of this malignancy radiotherapy. However, 
sequential and/or concurrent chemotherapy is also majorly applied for the 
treatment of NPC due to its sensitivity for chemotherapy. It had been known 
that concurrent chemoradiotherapy (CCRT) with/without adjuvant 
chemotherapy is recommended for NPC cases with locoregionally 
metastasis while radiotherapy alone is suggested for stage I NPC patients. 
Stage II NPC is preferably treated with CCRT [5, 6]. Chen et al. in their 
phase III randomized trial showed that adding concurrent chemotherapy to 
two-dimensional radiotherapy (2D-RT) in NPC treatment was significantly 
improved overall survival.[7].  
Squamous Cell Carcinoma of the Head and Neck (SCCHN) has 
550,000 cases worldwide annually [8].  Traditionally surgery and 
radiotherapy (RT) either alone for early stage disease or in combination for 
NPC cases with locoregionally metastasis were thought to have curative 
potential [9, 10]. 
Moertel et al. classifying the second primary tumor in the order in 
which the tumor appeared diagnosed simultaneously or during the first 6 
months since the primary tumor was diagnosed, and the time the tumor was 
diagnosed after that time period [11]. 
The differential diagnosis between metastasis and primary malignancy 
remains one of the most challenging tasks. Differentiating malignant tumors 
that spread from local tumor growth has a great influence on the patient's 
prognosis and can rationally guide developing therapeutic strategies [12]. 
1.1  Radiotherapy 
Nasopharyngeal cancer is largely a radioresponse type so radiotherapy 
has a very large role in the treatment of KNF for all stages without distant 
metastases. Patients with distant metastases can be treated with radiotherapy 
with the aim of local control for the improvement of the quality life of 
patients. The management of radiotherapy given in the form of external 
radiation with conventional 2-dimensional (2D) techniques, 3-dimensional 
conformal techniques (3DCRT) and Intensity Modulated Radiotherapy 
(IMRT) techniques. IMRT is the highest form of radial conformal technique 
that gives high doses to tumor targets while providing low dose conformity 
to the surrounding healthy tissue by using multiple beam directions which 
can provide radiation conformity according to the shape of the target [13]. 
The selection of radiotherapy techniques is based on clinical indications 
and modalities owned by each health institution. The higher the technique 
used, the radiation side effects will be lower. The side effects of xerostomia 
were lower in the IMRT technique compared to conventional 2D techniques 
which was 39.3% vs 82.1%. The radiotherapy dose given when using 
conventional 2D techniques is 66 Gy at an early stage and 70 Gy at a higher 
stage with a dose per fraction of 2 Gy, carried out 5 fractions every 1 week. 
For the IMRT technique the total dose given is 70 Gy in 33 fractions (2.12 
Gy per fraction) [14]. 
1.2 Chemotherapy 
Management of advanced locoregional NPC is to use a combination of 
radiotherapy and chemotherapy. Chemotherapy can be given before, during, 
or after radiation or is known as neoajuvan, concurrent, and adjuvant 
chemotherapy. The choice of chemotherapy is individualized according to 
the patient's characteristics. Standard chemotherapy for chemoradiation in 
advanced local conditions is concurrent cisplatin with radiotherapy. 
Meanwhile for chemoradiation followed by adjuvant chemotherapy can be 
used cisplatin + radiotherapy followed by cisplatin/5-FU or carboplatin/5 
FU. For neoadjuvant chemotherapy the regimen used is 
docetaxel/cisplatin/5 FI, docetaxel/cisplatin. Cisplatin/5 FU, 
cisplatin/epirubicin/paclitaxel which are then followed by concordant 
coordination with the administration of cisplatin or carboplatin weekly [15].  
 
A 39 years old man was admitted to ENT-HN inpatients in RSPAD. He 
had complain reccurent spontaneous bleeding from his left nostrils for about 
4 months, noise in his ears, stuffy nose, and snoring. No other complaint 
from her head, eyes or neck. For about 2 months after, he complain for a 
mass in his right neck and mild headache. He has overweight and history of 
smoking, drink alcohol, and consume salted fish Clinical examination show 
enlargement lymphnodes about 1 cm in level II. Picture 1. CT scan 
examination were performed January 2018 and show a mass in 
nasopharyngeal. 
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Picture 1. CT Scan nasopharyng before chemoradiation January 2018 
(coronal and axial view) 
Biopsy test was undifferentiated nonkeratinizing carcinoma of 
nasopharyngeal, (WHO-3) and pathologic uptakes in bilateral lymph nodes 
from level II to V. Staging were done and the patient was diagnosed with 
stage III nasopharyngeal carcinoma. Thereafter, the patient received one 
cycle concurrent chemoradiotherapy for around 3 months using Cisplatin 
40mg/m2 every week for 6 time and 7000 cGy radiotherapy with 200cGy 
for 35 shot per each. The chemoradioation finished in end June 2018. 
Radiological evaluation after concurrent chemoradiotherapy (CT Scan in 
October 2018) still indicates no progress as the result of the therapy but in 
clinical examination the patient show recovery progress. Picture 2 and 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 2. Patient profile before and after chemoradiotherapy. 
 
 
 
Picture 3. CT Scan  nasopharyng after chemoradiation October 2018. 
 
Thereafter, Whole Body PET CT-Scan was performed in October 2018 
from laboratory Dharmais hospital to re-evaluate the radiological 
examination (CT-Scan from RSPAD, June 2018) and show complete 
response from the chemoradiotherapy that say no residive mass in 
nasopharyng, no bilateral juguler lymphadenopathy , no pathologic in head 
and neck area, lungs, mediastinum, abdomen, pelvic and nor the skeletal 
(Picture 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 4. PET-CT Scan nasopharyng after chemoradiation October 2018 
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2. DISCUSSION 
The lateral wall of the nasopharynx is known to be the most common site 
of primary NPC, particularly the fossa of Rosenmüller. Symptoms and sign of 
NPC usually are nonspecific such as nasal obstruction, auditory abnormalities, 
headache, and cranial nerve palsies, mainly nerves III, V, VI, and XII.  
The classification of NPC according to the World Health Organization 
(WHO) classification NPCs are classified into keratinizing squamous cell 
carcinoma (type I), differentiated non-keratinizing carcinoma (type II), and 
undifferentiated carcinoma (type III). 
There, it is still controversy in the optimal medicine, time, dose and 
duration of chemotherapy. As is well known, three different ways to give 
chemotheraphy in addition with radiotherapy: before (neoadjuvant), while 
(concurrent), and after (adjuvant) radiation therapy.  
The choice of treatment for locoregionally metastatic NPC cases are 
concurrent chemoradiotherapy (CCRT) with and without adjuvant 
chemotherapy. However, the stage I NPC cases is considered to be treated 
with radiotherapy alone and stage II NPC with CCRT. A phase III 
randomized trial by Chen et al. showed that NPC treatment by adding 
concurrent chemotherapy to two-dimensional radiotherapy (2D-RT) was 
significantly improved overall survival. For stage III/IV NPC, the 
chemotherapy combine with radiotherapy without metastasis based on 
consideration. The radiotherapy anti tumour strengthen simultaneously by 
radiosensitizer effect of chemotherapy. The systemic activity of 
chemotherapy would eradicate of the area outside chemotherapy 
micrometastasis. Finally, strengthen cell distribution which are sensitive to 
chemoradiotherapy and will increase transmission of the drug and result as 
the decrease the size of tumour size.. 
3. CONCLUSION 
Concurrent chemoradiation is one of the treatments for undifferentiated 
nasopharyngeal carcinoma stage III that can improve survival of the patient. 
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